Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Peripheral Arterial Disease | 20 | 2024 | 1311 | 3.010 |
Why?
|
Intermittent Claudication | 6 | 2023 | 300 | 2.590 |
Why?
|
Stents | 22 | 2021 | 3213 | 1.850 |
Why?
|
Lower Extremity | 13 | 2024 | 1226 | 1.680 |
Why?
|
Angioplasty, Balloon, Coronary | 14 | 2020 | 1727 | 1.560 |
Why?
|
Coronary Artery Disease | 32 | 2024 | 6546 | 1.450 |
Why?
|
Drug-Eluting Stents | 6 | 2023 | 683 | 1.420 |
Why?
|
Ticlopidine | 5 | 2016 | 731 | 1.420 |
Why?
|
Femoral Artery | 7 | 2023 | 811 | 1.340 |
Why?
|
Ischemia | 8 | 2023 | 1909 | 1.310 |
Why?
|
Platelet Aggregation Inhibitors | 9 | 2023 | 2770 | 1.270 |
Why?
|
Heptanoic Acids | 9 | 2009 | 344 | 1.260 |
Why?
|
Acute Coronary Syndrome | 7 | 2023 | 2184 | 1.220 |
Why?
|
Endovascular Procedures | 6 | 2023 | 2222 | 1.110 |
Why?
|
Endothelium, Vascular | 30 | 2014 | 4427 | 1.010 |
Why?
|
Coronary Disease | 20 | 2008 | 5912 | 1.010 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 14 | 2012 | 3251 | 0.990 |
Why?
|
Ultrasonography, Interventional | 12 | 2019 | 1531 | 0.980 |
Why?
|
Pyrroles | 9 | 2009 | 1119 | 0.940 |
Why?
|
Angioplasty, Balloon | 7 | 2020 | 608 | 0.930 |
Why?
|
Leg | 3 | 2016 | 1080 | 0.920 |
Why?
|
Cardiology | 9 | 2024 | 1702 | 0.890 |
Why?
|
Angioplasty | 4 | 2020 | 352 | 0.850 |
Why?
|
Angina Pectoris | 6 | 2009 | 956 | 0.820 |
Why?
|
Myocardial Infarction | 24 | 2024 | 11501 | 0.800 |
Why?
|
Coronary Artery Bypass | 9 | 2024 | 2186 | 0.790 |
Why?
|
C-Reactive Protein | 9 | 2013 | 3850 | 0.710 |
Why?
|
Vasodilation | 10 | 2019 | 970 | 0.690 |
Why?
|
Anticholesteremic Agents | 9 | 2009 | 970 | 0.670 |
Why?
|
Angina, Unstable | 5 | 2004 | 893 | 0.660 |
Why?
|
Arteriosclerosis | 14 | 2004 | 1053 | 0.640 |
Why?
|
Metals | 3 | 2015 | 710 | 0.640 |
Why?
|
United States Department of Veterans Affairs | 4 | 2024 | 934 | 0.610 |
Why?
|
Persian Gulf Syndrome | 1 | 2019 | 48 | 0.610 |
Why?
|
Vascular Resistance | 4 | 2019 | 941 | 0.610 |
Why?
|
Coronary Vasospasm | 2 | 2014 | 81 | 0.600 |
Why?
|
Vascular Patency | 6 | 2023 | 912 | 0.600 |
Why?
|
Coronary Stenosis | 4 | 2018 | 800 | 0.590 |
Why?
|
Veterans | 2 | 2023 | 2664 | 0.590 |
Why?
|
Popliteal Artery | 3 | 2023 | 301 | 0.540 |
Why?
|
Coronary Vessels | 13 | 2014 | 3097 | 0.540 |
Why?
|
Withholding Treatment | 1 | 2021 | 621 | 0.540 |
Why?
|
American Heart Association | 5 | 2024 | 1047 | 0.540 |
Why?
|
Coronary Angiography | 16 | 2014 | 4494 | 0.520 |
Why?
|
Arterial Occlusive Diseases | 2 | 2011 | 729 | 0.520 |
Why?
|
Cholesterol, LDL | 13 | 2009 | 2393 | 0.470 |
Why?
|
Microvessels | 1 | 2019 | 591 | 0.460 |
Why?
|
Licensure, Medical | 1 | 2014 | 72 | 0.440 |
Why?
|
Acetylcholine | 4 | 2014 | 626 | 0.440 |
Why?
|
Vascular Surgical Procedures | 4 | 2017 | 1485 | 0.430 |
Why?
|
Treatment Outcome | 35 | 2024 | 65189 | 0.430 |
Why?
|
Hypolipidemic Agents | 5 | 2002 | 608 | 0.430 |
Why?
|
Atrial Fibrillation | 6 | 2024 | 5189 | 0.420 |
Why?
|
Vitamin E | 6 | 2006 | 869 | 0.420 |
Why?
|
Myocardial Revascularization | 2 | 2011 | 793 | 0.410 |
Why?
|
Specialty Boards | 1 | 2014 | 234 | 0.410 |
Why?
|
Myocardial Ischemia | 8 | 2014 | 2128 | 0.410 |
Why?
|
Aortic Rupture | 1 | 2015 | 303 | 0.400 |
Why?
|
Hemorrhage | 6 | 2024 | 3461 | 0.390 |
Why?
|
Cardiovascular Agents | 2 | 2018 | 851 | 0.390 |
Why?
|
Drug Therapy, Combination | 8 | 2023 | 6309 | 0.390 |
Why?
|
Humans | 162 | 2024 | 765956 | 0.390 |
Why?
|
Amlodipine | 1 | 2012 | 84 | 0.390 |
Why?
|
Risk Factors | 41 | 2024 | 74836 | 0.380 |
Why?
|
Drug Administration Schedule | 5 | 2021 | 4850 | 0.380 |
Why?
|
Aspirin | 3 | 2023 | 3134 | 0.370 |
Why?
|
Coronary Sinus | 1 | 2012 | 85 | 0.370 |
Why?
|
Serum Amyloid A Protein | 3 | 2013 | 127 | 0.360 |
Why?
|
Cardiac Resynchronization Therapy Devices | 1 | 2012 | 122 | 0.360 |
Why?
|
Ascorbic Acid | 6 | 2006 | 657 | 0.350 |
Why?
|
Septal Occluder Device | 1 | 2011 | 127 | 0.350 |
Why?
|
Coronary Thrombosis | 2 | 2020 | 440 | 0.350 |
Why?
|
Blood Vessels | 1 | 2016 | 1113 | 0.350 |
Why?
|
Guidelines as Topic | 1 | 2017 | 1394 | 0.350 |
Why?
|
Gastrointestinal Tract | 1 | 2016 | 834 | 0.340 |
Why?
|
Enalapril | 1 | 2012 | 317 | 0.340 |
Why?
|
Disease Management | 4 | 2017 | 2535 | 0.340 |
Why?
|
Mastitis | 2 | 2001 | 41 | 0.330 |
Why?
|
Foreign-Body Migration | 1 | 2011 | 220 | 0.330 |
Why?
|
Cholesterol | 8 | 1999 | 2898 | 0.330 |
Why?
|
Aorta, Thoracic | 2 | 2015 | 1103 | 0.320 |
Why?
|
Graft Occlusion, Vascular | 4 | 2020 | 540 | 0.320 |
Why?
|
Subclavian Steal Syndrome | 1 | 2009 | 22 | 0.320 |
Why?
|
Foramen Ovale, Patent | 1 | 2011 | 211 | 0.310 |
Why?
|
Peripheral Vascular Diseases | 1 | 2012 | 516 | 0.310 |
Why?
|
Subclavian Artery | 1 | 2009 | 136 | 0.310 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2015 | 700 | 0.310 |
Why?
|
Blood Flow Velocity | 5 | 2019 | 1381 | 0.310 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 1145 | 0.310 |
Why?
|
Embolism | 1 | 2011 | 400 | 0.300 |
Why?
|
Vascular Diseases | 1 | 2016 | 1159 | 0.290 |
Why?
|
Endothelin-1 | 3 | 2009 | 295 | 0.290 |
Why?
|
Cause of Death | 3 | 2024 | 3708 | 0.290 |
Why?
|
Limb Salvage | 3 | 2023 | 488 | 0.290 |
Why?
|
Antioxidants | 6 | 2006 | 1670 | 0.280 |
Why?
|
Proportional Hazards Models | 9 | 2024 | 12509 | 0.280 |
Why?
|
Propensity Score | 4 | 2016 | 1968 | 0.280 |
Why?
|
Male | 86 | 2024 | 363691 | 0.270 |
Why?
|
Prosthesis Design | 4 | 2016 | 2105 | 0.270 |
Why?
|
Vasomotor System | 6 | 2005 | 207 | 0.270 |
Why?
|
Neovascularization, Physiologic | 1 | 2014 | 1375 | 0.270 |
Why?
|
Multivariate Analysis | 10 | 2016 | 12057 | 0.260 |
Why?
|
Antihypertensive Agents | 3 | 2012 | 2033 | 0.260 |
Why?
|
Arteriovenous Shunt, Surgical | 1 | 2009 | 290 | 0.260 |
Why?
|
Time Factors | 21 | 2024 | 40065 | 0.260 |
Why?
|
Endarterectomy, Carotid | 1 | 2011 | 557 | 0.250 |
Why?
|
Arteries | 3 | 2018 | 1118 | 0.250 |
Why?
|
Ambulatory Care Facilities | 1 | 2011 | 939 | 0.250 |
Why?
|
Middle Aged | 69 | 2024 | 223004 | 0.250 |
Why?
|
CD40 Ligand | 2 | 2004 | 528 | 0.240 |
Why?
|
Electrocardiography | 9 | 2013 | 6404 | 0.230 |
Why?
|
Ankle Brachial Index | 2 | 2018 | 166 | 0.230 |
Why?
|
Upper Extremity | 1 | 2009 | 682 | 0.230 |
Why?
|
Tissue Plasminogen Activator | 2 | 2013 | 1167 | 0.230 |
Why?
|
Randomized Controlled Trials as Topic | 5 | 2017 | 10383 | 0.230 |
Why?
|
Mitral Valve Insufficiency | 2 | 2024 | 1414 | 0.230 |
Why?
|
Advisory Committees | 3 | 2017 | 796 | 0.230 |
Why?
|
Carotid Stenosis | 1 | 2011 | 861 | 0.220 |
Why?
|
Vasoconstriction | 2 | 2009 | 594 | 0.220 |
Why?
|
Saphenous Vein | 3 | 2024 | 511 | 0.220 |
Why?
|
Fibrinolytic Agents | 2 | 2023 | 2080 | 0.210 |
Why?
|
Coronary Restenosis | 2 | 2003 | 396 | 0.210 |
Why?
|
Coronary Circulation | 7 | 2009 | 1602 | 0.210 |
Why?
|
Stroke | 5 | 2024 | 9747 | 0.210 |
Why?
|
Angioplasty, Balloon, Laser-Assisted | 1 | 2002 | 21 | 0.200 |
Why?
|
Lovastatin | 2 | 2002 | 114 | 0.200 |
Why?
|
Aged | 49 | 2024 | 171114 | 0.200 |
Why?
|
Practice Guidelines as Topic | 4 | 2016 | 7425 | 0.200 |
Why?
|
Drug Prescriptions | 1 | 2012 | 1662 | 0.200 |
Why?
|
Female | 72 | 2024 | 396101 | 0.200 |
Why?
|
Nitric Oxide | 6 | 2001 | 2143 | 0.200 |
Why?
|
Anticoagulants | 5 | 2024 | 4862 | 0.200 |
Why?
|
Postoperative Care | 2 | 2021 | 1470 | 0.190 |
Why?
|
Syndrome | 6 | 2003 | 3271 | 0.190 |
Why?
|
Breast Feeding | 2 | 2001 | 1363 | 0.190 |
Why?
|
United States | 19 | 2024 | 72898 | 0.190 |
Why?
|
Boston | 3 | 2023 | 9338 | 0.180 |
Why?
|
Constriction, Pathologic | 4 | 2018 | 1105 | 0.180 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2015 | 2310 | 0.180 |
Why?
|
Biomedical Research | 2 | 2016 | 3458 | 0.180 |
Why?
|
Inflammation Mediators | 2 | 2013 | 1884 | 0.180 |
Why?
|
Cardiac Resynchronization Therapy | 2 | 2024 | 562 | 0.180 |
Why?
|
Atherosclerosis | 4 | 2014 | 3425 | 0.180 |
Why?
|
Diet Surveys | 2 | 1997 | 1159 | 0.170 |
Why?
|
Clinical Competence | 3 | 2014 | 4863 | 0.170 |
Why?
|
Renal Dialysis | 1 | 2009 | 1799 | 0.170 |
Why?
|
Tricuspid Valve Insufficiency | 1 | 2024 | 363 | 0.170 |
Why?
|
Ambulatory Care | 1 | 2011 | 2778 | 0.170 |
Why?
|
Lipoproteins, LDL | 6 | 2005 | 643 | 0.170 |
Why?
|
Laboratories | 3 | 2012 | 462 | 0.170 |
Why?
|
Defibrillators, Implantable | 2 | 2024 | 1490 | 0.160 |
Why?
|
Brachial Artery | 5 | 2004 | 375 | 0.160 |
Why?
|
New South Wales | 6 | 2001 | 69 | 0.160 |
Why?
|
Australia | 8 | 2013 | 1258 | 0.160 |
Why?
|
Endpoint Determination | 2 | 2013 | 591 | 0.160 |
Why?
|
Fibrinogen | 2 | 1993 | 895 | 0.160 |
Why?
|
Secondary Prevention | 3 | 2012 | 1472 | 0.160 |
Why?
|
Hospital Mortality | 3 | 2013 | 5343 | 0.160 |
Why?
|
Risk Assessment | 10 | 2024 | 24283 | 0.160 |
Why?
|
Pacemaker, Artificial | 1 | 2024 | 827 | 0.150 |
Why?
|
Emergency Treatment | 2 | 2012 | 494 | 0.150 |
Why?
|
Brain Ischemia | 1 | 2011 | 3000 | 0.150 |
Why?
|
Hypercholesterolemia | 6 | 2003 | 1149 | 0.150 |
Why?
|
Nitroglycerin | 5 | 2002 | 331 | 0.150 |
Why?
|
Recurrence | 8 | 2013 | 8501 | 0.140 |
Why?
|
Societies, Medical | 3 | 2024 | 3956 | 0.140 |
Why?
|
Acute Disease | 6 | 2003 | 7232 | 0.140 |
Why?
|
Diabetes Mellitus | 1 | 2015 | 5891 | 0.140 |
Why?
|
Logistic Models | 5 | 2016 | 13266 | 0.130 |
Why?
|
Dietary Fats | 2 | 1997 | 2002 | 0.130 |
Why?
|
Analysis of Variance | 3 | 2015 | 6203 | 0.130 |
Why?
|
Cardiac Surgical Procedures | 1 | 2011 | 3675 | 0.130 |
Why?
|
Immunodiffusion | 2 | 1993 | 140 | 0.130 |
Why?
|
Quality of Life | 4 | 2022 | 13461 | 0.130 |
Why?
|
Veterans Disability Claims | 1 | 2015 | 24 | 0.130 |
Why?
|
Risk | 4 | 2009 | 9591 | 0.130 |
Why?
|
Societies, Scientific | 1 | 2017 | 221 | 0.130 |
Why?
|
Dietary Fats, Unsaturated | 1 | 1997 | 223 | 0.130 |
Why?
|
Heart Transplantation | 6 | 2009 | 3310 | 0.120 |
Why?
|
Follow-Up Studies | 12 | 2021 | 39194 | 0.120 |
Why?
|
Puerperal Disorders | 1 | 1998 | 305 | 0.120 |
Why?
|
Cardiac Imaging Techniques | 1 | 2018 | 280 | 0.120 |
Why?
|
Predictive Value of Tests | 10 | 2018 | 15398 | 0.120 |
Why?
|
Cardiovascular Diseases | 3 | 2012 | 15651 | 0.120 |
Why?
|
Retreatment | 2 | 2011 | 598 | 0.120 |
Why?
|
Writing | 1 | 2017 | 199 | 0.120 |
Why?
|
Nitrates | 1 | 1996 | 260 | 0.120 |
Why?
|
Double-Blind Method | 9 | 2020 | 12437 | 0.120 |
Why?
|
Heart Failure | 3 | 2024 | 11840 | 0.120 |
Why?
|
Retrospective Studies | 12 | 2024 | 81515 | 0.120 |
Why?
|
Lipoprotein(a) | 3 | 2009 | 488 | 0.120 |
Why?
|
Magnesium Sulfate | 1 | 1995 | 74 | 0.120 |
Why?
|
Hospitals, Veterans | 1 | 2016 | 395 | 0.110 |
Why?
|
Registries | 6 | 2019 | 8297 | 0.110 |
Why?
|
Electrocardiography, Ambulatory | 2 | 2000 | 582 | 0.110 |
Why?
|
Odds Ratio | 7 | 2013 | 9649 | 0.110 |
Why?
|
Stroke Volume | 3 | 2024 | 5596 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 3 | 2014 | 20660 | 0.110 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2018 | 345 | 0.110 |
Why?
|
Severity of Illness Index | 4 | 2018 | 15880 | 0.110 |
Why?
|
Inflammation | 6 | 2009 | 10850 | 0.110 |
Why?
|
Digoxin | 1 | 1995 | 246 | 0.110 |
Why?
|
Adult | 40 | 2019 | 223038 | 0.110 |
Why?
|
Salicylates | 1 | 2014 | 125 | 0.110 |
Why?
|
Cost-Benefit Analysis | 5 | 2019 | 5526 | 0.100 |
Why?
|
Calcinosis | 1 | 2001 | 1479 | 0.100 |
Why?
|
Regional Blood Flow | 5 | 2009 | 1478 | 0.100 |
Why?
|
Neopterin | 1 | 2012 | 57 | 0.100 |
Why?
|
Apolipoproteins B | 2 | 2009 | 384 | 0.100 |
Why?
|
Reproducibility of Results | 9 | 2019 | 20125 | 0.100 |
Why?
|
Edetic Acid | 1 | 1992 | 274 | 0.090 |
Why?
|
Hemodynamics | 6 | 2012 | 4183 | 0.090 |
Why?
|
Thrombosis | 4 | 2012 | 2949 | 0.090 |
Why?
|
Long-Term Care | 1 | 2015 | 629 | 0.090 |
Why?
|
Atherectomy, Coronary | 2 | 2001 | 137 | 0.090 |
Why?
|
Receptors, Interleukin-1 | 1 | 2012 | 260 | 0.090 |
Why?
|
Ventricular Function, Left | 1 | 2024 | 3928 | 0.090 |
Why?
|
Epoprostenol | 1 | 2012 | 246 | 0.090 |
Why?
|
Exercise | 2 | 2018 | 5937 | 0.090 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2012 | 153 | 0.090 |
Why?
|
Apolipoproteins A | 1 | 1991 | 94 | 0.090 |
Why?
|
Databases, Factual | 2 | 2016 | 8067 | 0.090 |
Why?
|
Interleukin-18 | 1 | 2012 | 251 | 0.090 |
Why?
|
Hospitals, Teaching | 2 | 1996 | 1158 | 0.090 |
Why?
|
Aged, 80 and over | 14 | 2024 | 59488 | 0.090 |
Why?
|
Pulmonary Veno-Occlusive Disease | 1 | 2010 | 64 | 0.090 |
Why?
|
Ultrasonography, Doppler, Duplex | 1 | 2011 | 208 | 0.080 |
Why?
|
Hypertrophy, Left Ventricular | 2 | 2012 | 855 | 0.080 |
Why?
|
Family Practice | 4 | 1998 | 508 | 0.080 |
Why?
|
Drug Therapy | 1 | 2013 | 504 | 0.080 |
Why?
|
Quality Indicators, Health Care | 3 | 2014 | 1806 | 0.080 |
Why?
|
Device Removal | 2 | 2011 | 646 | 0.080 |
Why?
|
Receptor, Endothelin A | 3 | 2009 | 55 | 0.080 |
Why?
|
Quality Assurance, Health Care | 3 | 2014 | 2172 | 0.080 |
Why?
|
Angiography | 2 | 2019 | 1581 | 0.080 |
Why?
|
Energy Intake | 1 | 1997 | 2140 | 0.080 |
Why?
|
Utilization Review | 1 | 1991 | 381 | 0.080 |
Why?
|
Heart Arrest | 2 | 2013 | 1516 | 0.080 |
Why?
|
Pulmonary Artery | 2 | 2012 | 1935 | 0.080 |
Why?
|
Vasodilator Agents | 4 | 2014 | 988 | 0.080 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2012 | 636 | 0.080 |
Why?
|
History, 21st Century | 1 | 2014 | 1574 | 0.080 |
Why?
|
Incidental Findings | 1 | 2013 | 697 | 0.080 |
Why?
|
Asymptomatic Diseases | 1 | 2011 | 586 | 0.080 |
Why?
|
Catheters | 1 | 2011 | 426 | 0.080 |
Why?
|
Interleukin-6 | 3 | 2013 | 3222 | 0.070 |
Why?
|
Cholesterol, HDL | 4 | 2003 | 1811 | 0.070 |
Why?
|
Chi-Square Distribution | 2 | 2012 | 3432 | 0.070 |
Why?
|
Prognosis | 6 | 2024 | 29921 | 0.070 |
Why?
|
Blood Pressure | 4 | 2003 | 8532 | 0.070 |
Why?
|
Stress, Mechanical | 5 | 2007 | 1669 | 0.070 |
Why?
|
Postoperative Complications | 3 | 2024 | 15747 | 0.070 |
Why?
|
Host-Pathogen Interactions | 1 | 2016 | 1461 | 0.070 |
Why?
|
Educational Measurement | 1 | 2014 | 1260 | 0.070 |
Why?
|
Iliac Artery | 2 | 2007 | 330 | 0.070 |
Why?
|
Prosthesis Implantation | 1 | 2012 | 595 | 0.070 |
Why?
|
Disease Progression | 8 | 2013 | 13631 | 0.070 |
Why?
|
Endocarditis, Bacterial | 1 | 2011 | 434 | 0.070 |
Why?
|
Epidemiologic Methods | 1 | 1992 | 1326 | 0.070 |
Why?
|
Cohort Studies | 6 | 2015 | 41647 | 0.070 |
Why?
|
Survival Rate | 3 | 2023 | 12795 | 0.070 |
Why?
|
Physical Therapy Modalities | 1 | 1991 | 533 | 0.070 |
Why?
|
Forecasting | 1 | 2016 | 2936 | 0.070 |
Why?
|
Peptides, Cyclic | 3 | 2009 | 390 | 0.070 |
Why?
|
Hospitalization | 3 | 2024 | 10808 | 0.070 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2009 | 428 | 0.070 |
Why?
|
Heart Conduction System | 1 | 2012 | 1006 | 0.070 |
Why?
|
Early Diagnosis | 1 | 2011 | 1187 | 0.070 |
Why?
|
Blood Chemical Analysis | 1 | 1988 | 433 | 0.070 |
Why?
|
Glomerular Filtration Rate | 1 | 2015 | 2233 | 0.070 |
Why?
|
Triglycerides | 4 | 2003 | 2441 | 0.070 |
Why?
|
Prosthesis-Related Infections | 1 | 2011 | 496 | 0.060 |
Why?
|
Arrhythmias, Cardiac | 1 | 1996 | 2247 | 0.060 |
Why?
|
Tachycardia, Ventricular | 1 | 1995 | 1310 | 0.060 |
Why?
|
Azetidines | 1 | 2007 | 150 | 0.060 |
Why?
|
Preventive Medicine | 1 | 1987 | 246 | 0.060 |
Why?
|
Phospholipids | 1 | 2009 | 776 | 0.060 |
Why?
|
Patient Selection | 3 | 2012 | 4255 | 0.060 |
Why?
|
Respiratory Tract Diseases | 1 | 1991 | 744 | 0.060 |
Why?
|
Anaphylaxis | 1 | 2012 | 739 | 0.060 |
Why?
|
Mass Screening | 3 | 1990 | 5445 | 0.060 |
Why?
|
Echocardiography, Three-Dimensional | 1 | 2010 | 611 | 0.060 |
Why?
|
Pulmonary Veins | 1 | 2010 | 757 | 0.060 |
Why?
|
Lipid Metabolism | 2 | 2005 | 1892 | 0.060 |
Why?
|
Exercise Test | 3 | 2018 | 2180 | 0.060 |
Why?
|
Evidence-Based Medicine | 3 | 2016 | 3685 | 0.060 |
Why?
|
Mammary Arteries | 1 | 2024 | 81 | 0.060 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 2268 | 0.060 |
Why?
|
Sensitivity and Specificity | 5 | 2018 | 14652 | 0.050 |
Why?
|
Gadolinium DTPA | 1 | 2007 | 823 | 0.050 |
Why?
|
Oxidative Stress | 3 | 2006 | 3141 | 0.050 |
Why?
|
Incidence | 5 | 2013 | 21480 | 0.050 |
Why?
|
Radial Artery | 1 | 2024 | 189 | 0.050 |
Why?
|
Professional Review Organizations | 2 | 2012 | 48 | 0.050 |
Why?
|
Solubility | 1 | 2004 | 1078 | 0.050 |
Why?
|
Treatment Failure | 1 | 2008 | 2652 | 0.050 |
Why?
|
Echocardiography | 2 | 2011 | 5045 | 0.050 |
Why?
|
Animals | 9 | 2022 | 168759 | 0.050 |
Why?
|
omega-N-Methylarginine | 1 | 2001 | 108 | 0.050 |
Why?
|
Compliance | 1 | 2001 | 100 | 0.050 |
Why?
|
Clinical Trials as Topic | 2 | 2023 | 8041 | 0.050 |
Why?
|
Nitric Oxide Donors | 1 | 2001 | 122 | 0.050 |
Why?
|
Anatomy, Cross-Sectional | 1 | 2001 | 139 | 0.050 |
Why?
|
Cell Adhesion Molecules | 2 | 1998 | 1612 | 0.050 |
Why?
|
Regression Analysis | 1 | 2011 | 6321 | 0.050 |
Why?
|
Apolipoproteins | 1 | 2003 | 327 | 0.050 |
Why?
|
Reactive Oxygen Species | 1 | 2009 | 2140 | 0.050 |
Why?
|
Contrast Media | 2 | 2012 | 5329 | 0.050 |
Why?
|
Hypertension, Pulmonary | 1 | 2012 | 1604 | 0.040 |
Why?
|
Cardiovascular Surgical Procedures | 2 | 2012 | 193 | 0.040 |
Why?
|
Insulin | 1 | 2015 | 6599 | 0.040 |
Why?
|
Total Quality Management | 2 | 2012 | 264 | 0.040 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2011 | 2136 | 0.040 |
Why?
|
Blood Coagulation | 2 | 2024 | 1166 | 0.040 |
Why?
|
Cardiac Pacing, Artificial | 1 | 2024 | 881 | 0.040 |
Why?
|
Heart Diseases | 2 | 1990 | 2821 | 0.040 |
Why?
|
Kidney | 1 | 2015 | 7066 | 0.040 |
Why?
|
Troponin | 1 | 2003 | 533 | 0.040 |
Why?
|
ROC Curve | 1 | 2007 | 3620 | 0.040 |
Why?
|
Elasticity | 1 | 2001 | 652 | 0.040 |
Why?
|
Heart Ventricles | 1 | 2011 | 3832 | 0.040 |
Why?
|
Terrorism | 1 | 2002 | 211 | 0.040 |
Why?
|
Linear Models | 4 | 2013 | 5876 | 0.040 |
Why?
|
Developing Countries | 2 | 2003 | 2911 | 0.040 |
Why?
|
Inguinal Canal | 1 | 2019 | 71 | 0.040 |
Why?
|
Chlamydophila pneumoniae | 1 | 1998 | 53 | 0.040 |
Why?
|
Autoantibodies | 2 | 2009 | 2113 | 0.040 |
Why?
|
Evaluation Studies as Topic | 2 | 1991 | 1600 | 0.040 |
Why?
|
Health Behavior | 1 | 1990 | 2650 | 0.040 |
Why?
|
Radiography | 1 | 2009 | 6919 | 0.040 |
Why?
|
Platelet Activation | 1 | 2002 | 645 | 0.040 |
Why?
|
Hypertension | 2 | 2012 | 8626 | 0.040 |
Why?
|
Cross-Over Studies | 2 | 2014 | 2108 | 0.040 |
Why?
|
Pyridones | 1 | 2024 | 816 | 0.040 |
Why?
|
Nitric Oxide Synthase | 1 | 2001 | 911 | 0.040 |
Why?
|
Coronary Vessel Anomalies | 1 | 2001 | 307 | 0.040 |
Why?
|
Massachusetts | 1 | 2011 | 8871 | 0.040 |
Why?
|
Education, Medical, Undergraduate | 1 | 1987 | 1085 | 0.040 |
Why?
|
Vasoconstrictor Agents | 1 | 2001 | 655 | 0.040 |
Why?
|
Unnecessary Procedures | 1 | 2001 | 416 | 0.040 |
Why?
|
Chronic Disease | 2 | 2022 | 9347 | 0.040 |
Why?
|
Medicare | 1 | 2015 | 6823 | 0.030 |
Why?
|
Consensus | 2 | 2017 | 3202 | 0.030 |
Why?
|
Wettability | 1 | 1996 | 27 | 0.030 |
Why?
|
Catheter Ablation | 1 | 2010 | 2788 | 0.030 |
Why?
|
Ultrasonography | 4 | 2005 | 5993 | 0.030 |
Why?
|
Prospective Studies | 5 | 2020 | 54806 | 0.030 |
Why?
|
Administration, Sublingual | 1 | 1996 | 60 | 0.030 |
Why?
|
Combined Modality Therapy | 1 | 2008 | 8529 | 0.030 |
Why?
|
Absorption | 1 | 1996 | 242 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2005 | 10729 | 0.030 |
Why?
|
Cost Allocation | 1 | 1996 | 47 | 0.030 |
Why?
|
Patient Acceptance of Health Care | 1 | 1990 | 3229 | 0.030 |
Why?
|
Thrombectomy | 1 | 2001 | 681 | 0.030 |
Why?
|
Emergency Service, Hospital | 2 | 2012 | 7875 | 0.030 |
Why?
|
Infusions, Intravenous | 2 | 2012 | 2229 | 0.030 |
Why?
|
Diabetic Angiopathies | 1 | 2001 | 805 | 0.030 |
Why?
|
Ankle | 1 | 2019 | 353 | 0.030 |
Why?
|
Benchmarking | 2 | 2012 | 1052 | 0.030 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 2 | 2013 | 694 | 0.030 |
Why?
|
Chlamydia Infections | 1 | 1998 | 364 | 0.030 |
Why?
|
Physician's Role | 1 | 2002 | 927 | 0.030 |
Why?
|
Cross-Sectional Studies | 4 | 2024 | 26313 | 0.030 |
Why?
|
Health Services Accessibility | 1 | 2012 | 5506 | 0.030 |
Why?
|
Echocardiography, Transesophageal | 2 | 2011 | 1093 | 0.030 |
Why?
|
Death, Sudden, Cardiac | 1 | 2022 | 1568 | 0.030 |
Why?
|
Hospitals, Public | 1 | 1996 | 203 | 0.030 |
Why?
|
Cholestyramine Resin | 1 | 1994 | 25 | 0.030 |
Why?
|
Cytomegalovirus | 1 | 1998 | 751 | 0.030 |
Why?
|
Diabetes Complications | 1 | 2001 | 1316 | 0.030 |
Why?
|
Brachytherapy | 1 | 2001 | 1222 | 0.030 |
Why?
|
Pyrazoles | 1 | 2024 | 2033 | 0.030 |
Why?
|
Health Services | 1 | 1998 | 756 | 0.030 |
Why?
|
Rest | 1 | 2018 | 941 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2013 | 6832 | 0.030 |
Why?
|
Injections, Intravenous | 1 | 1995 | 1377 | 0.030 |
Why?
|
San Francisco | 1 | 2012 | 166 | 0.020 |
Why?
|
False Negative Reactions | 1 | 1993 | 573 | 0.020 |
Why?
|
Cytomegalovirus Infections | 1 | 1998 | 836 | 0.020 |
Why?
|
Prevalence | 2 | 2024 | 15839 | 0.020 |
Why?
|
Neutropenia | 1 | 1997 | 893 | 0.020 |
Why?
|
Lipids | 3 | 2005 | 3316 | 0.020 |
Why?
|
Ambulances | 1 | 2012 | 94 | 0.020 |
Why?
|
Exercise Therapy | 1 | 2019 | 937 | 0.020 |
Why?
|
Observer Variation | 2 | 2013 | 2615 | 0.020 |
Why?
|
Urban Health Services | 1 | 2012 | 176 | 0.020 |
Why?
|
Drainage, Postural | 1 | 1991 | 2 | 0.020 |
Why?
|
Percussion | 1 | 1991 | 17 | 0.020 |
Why?
|
Haemophilus influenzae | 1 | 2011 | 176 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2001 | 3715 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2001 | 4247 | 0.020 |
Why?
|
Medication Therapy Management | 1 | 2012 | 131 | 0.020 |
Why?
|
Patient Care Team | 2 | 2012 | 2517 | 0.020 |
Why?
|
Suction | 1 | 2011 | 265 | 0.020 |
Why?
|
Water | 1 | 1996 | 1417 | 0.020 |
Why?
|
Patient Admission | 1 | 1997 | 1365 | 0.020 |
Why?
|
Fever | 1 | 1997 | 1603 | 0.020 |
Why?
|
Education, Medical, Graduate | 2 | 2012 | 2418 | 0.020 |
Why?
|
False Positive Reactions | 1 | 2012 | 955 | 0.020 |
Why?
|
Heart Rate | 2 | 2003 | 4203 | 0.020 |
Why?
|
Sampling Studies | 1 | 1991 | 607 | 0.020 |
Why?
|
North America | 1 | 2013 | 1285 | 0.020 |
Why?
|
Hemoptysis | 1 | 2010 | 150 | 0.020 |
Why?
|
Peptides | 1 | 2001 | 4331 | 0.020 |
Why?
|
Attitude of Health Personnel | 1 | 2003 | 3925 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2007 | 36532 | 0.020 |
Why?
|
Community Health Nursing | 1 | 1988 | 22 | 0.020 |
Why?
|
Anti-Bacterial Agents | 3 | 2011 | 7478 | 0.020 |
Why?
|
Pneumonia | 1 | 2000 | 2157 | 0.020 |
Why?
|
Photometry | 1 | 1988 | 56 | 0.020 |
Why?
|
Reagent Strips | 1 | 1988 | 40 | 0.020 |
Why?
|
Medical History Taking | 1 | 2012 | 777 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 1994 | 1668 | 0.020 |
Why?
|
Smoking | 3 | 2003 | 9081 | 0.020 |
Why?
|
Sputum | 1 | 1991 | 513 | 0.020 |
Why?
|
Patient Compliance | 1 | 1998 | 2692 | 0.020 |
Why?
|
Case-Control Studies | 3 | 2009 | 22222 | 0.020 |
Why?
|
Troponin I | 1 | 2012 | 655 | 0.020 |
Why?
|
South Africa | 1 | 2013 | 1867 | 0.020 |
Why?
|
Emergencies | 1 | 2013 | 1223 | 0.020 |
Why?
|
Hemorheology | 1 | 2007 | 144 | 0.020 |
Why?
|
Drug Resistance | 1 | 2012 | 1591 | 0.020 |
Why?
|
Emergency Medical Services | 2 | 2012 | 1938 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2012 | 1441 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2011 | 2910 | 0.020 |
Why?
|
Cost of Illness | 1 | 1996 | 1950 | 0.020 |
Why?
|
Europe | 1 | 2013 | 3423 | 0.020 |
Why?
|
Elastic Tissue | 1 | 2005 | 66 | 0.020 |
Why?
|
Health Care Costs | 1 | 2019 | 3242 | 0.020 |
Why?
|
Heart Atria | 1 | 2011 | 1363 | 0.020 |
Why?
|
Catheterization | 1 | 2010 | 1425 | 0.010 |
Why?
|
Insulin Resistance | 2 | 2014 | 3985 | 0.010 |
Why?
|
Primary Prevention | 1 | 1992 | 1187 | 0.010 |
Why?
|
Immunoglobulin G | 2 | 2009 | 4528 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2001 | 8927 | 0.010 |
Why?
|
Microcirculation | 1 | 2009 | 1280 | 0.010 |
Why?
|
Immunoglobulin M | 1 | 2009 | 1528 | 0.010 |
Why?
|
Monitoring, Physiologic | 1 | 2012 | 1792 | 0.010 |
Why?
|
Diet Therapy | 1 | 2005 | 149 | 0.010 |
Why?
|
Health Education | 1 | 1990 | 1060 | 0.010 |
Why?
|
Equipment Design | 1 | 2011 | 3481 | 0.010 |
Why?
|
Blood Viscosity | 1 | 2003 | 125 | 0.010 |
Why?
|
Oxidation-Reduction | 1 | 2009 | 2218 | 0.010 |
Why?
|
Egypt | 1 | 2003 | 100 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 6499 | 0.010 |
Why?
|
Adolescent | 4 | 2002 | 88832 | 0.010 |
Why?
|
Thromboembolism | 1 | 2009 | 1003 | 0.010 |
Why?
|
Dyspnea | 1 | 2010 | 1352 | 0.010 |
Why?
|
Thailand | 1 | 2003 | 287 | 0.010 |
Why?
|
Philosophy, Medical | 1 | 2002 | 78 | 0.010 |
Why?
|
Sex Factors | 2 | 1997 | 10602 | 0.010 |
Why?
|
Beta Particles | 1 | 2001 | 52 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 2 | 2005 | 4034 | 0.010 |
Why?
|
Reference Values | 1 | 1988 | 4908 | 0.010 |
Why?
|
Phagocytes | 1 | 2002 | 292 | 0.010 |
Why?
|
Drug Evaluation | 1 | 2002 | 641 | 0.010 |
Why?
|
Forearm | 1 | 2003 | 427 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 1997 | 14749 | 0.010 |
Why?
|
Schools, Medical | 1 | 1987 | 876 | 0.010 |
Why?
|
Platelet Function Tests | 1 | 2002 | 275 | 0.010 |
Why?
|
Simvastatin | 1 | 2002 | 345 | 0.010 |
Why?
|
Kenya | 1 | 2003 | 758 | 0.010 |
Why?
|
Tunica Intima | 1 | 2002 | 455 | 0.010 |
Why?
|
Infant, Low Birth Weight | 1 | 1984 | 871 | 0.010 |
Why?
|
Biological Availability | 1 | 2000 | 385 | 0.010 |
Why?
|
Infant Mortality | 1 | 1984 | 751 | 0.010 |
Why?
|
Teaching | 1 | 1987 | 1169 | 0.010 |
Why?
|
Child | 3 | 2012 | 80563 | 0.010 |
Why?
|
Bibliometrics | 1 | 2003 | 357 | 0.010 |
Why?
|
Feeding Behavior | 1 | 1991 | 3211 | 0.010 |
Why?
|
Age Factors | 2 | 1997 | 18380 | 0.010 |
Why?
|
Living Donors | 1 | 2002 | 645 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 1991 | 4040 | 0.010 |
Why?
|
Publications | 1 | 2000 | 195 | 0.010 |
Why?
|
Hyperinsulinism | 1 | 2001 | 402 | 0.010 |
Why?
|
Hirudins | 1 | 1999 | 179 | 0.010 |
Why?
|
Referral and Consultation | 1 | 1991 | 3615 | 0.010 |
Why?
|
Length of Stay | 2 | 1997 | 6485 | 0.010 |
Why?
|
Oncology Service, Hospital | 1 | 1997 | 55 | 0.010 |
Why?
|
Seroepidemiologic Studies | 1 | 1998 | 404 | 0.010 |
Why?
|
Perfusion | 1 | 2002 | 1407 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2012 | 12976 | 0.010 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2000 | 1526 | 0.010 |
Why?
|
China | 1 | 2003 | 2385 | 0.010 |
Why?
|
Muscle, Smooth, Vascular | 1 | 2002 | 1499 | 0.010 |
Why?
|
India | 1 | 2003 | 2334 | 0.010 |
Why?
|
Telemedicine | 1 | 2013 | 3105 | 0.010 |
Why?
|
Hyperlipidemias | 1 | 2001 | 770 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 2002 | 1857 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2012 | 4415 | 0.010 |
Why?
|
Publishing | 1 | 2003 | 835 | 0.010 |
Why?
|
Physicians | 1 | 2013 | 4588 | 0.010 |
Why?
|
International Cooperation | 1 | 2002 | 1432 | 0.010 |
Why?
|
Creatine Kinase | 1 | 1997 | 682 | 0.010 |
Why?
|
Postoperative Period | 1 | 2000 | 1816 | 0.010 |
Why?
|
Macrophages | 2 | 2002 | 5772 | 0.010 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2001 | 1514 | 0.010 |
Why?
|
Rabbits | 1 | 2000 | 4734 | 0.010 |
Why?
|
Students, Medical | 1 | 1987 | 1959 | 0.010 |
Why?
|
Curriculum | 1 | 1987 | 3782 | 0.010 |
Why?
|
Leukocyte Count | 1 | 1997 | 1602 | 0.010 |
Why?
|
Blood Vessel Prosthesis Implantation | 1 | 2003 | 1434 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2006 | 4209 | 0.010 |
Why?
|
Health Care Surveys | 1 | 2000 | 2424 | 0.010 |
Why?
|
Protein Kinase C | 1 | 1997 | 1202 | 0.010 |
Why?
|
Isoenzymes | 1 | 1997 | 1689 | 0.010 |
Why?
|
Cell Division | 1 | 2000 | 4475 | 0.010 |
Why?
|
Hyperglycemia | 1 | 2001 | 1393 | 0.010 |
Why?
|
Diet | 1 | 1990 | 8086 | 0.010 |
Why?
|
Feasibility Studies | 1 | 2003 | 5302 | 0.010 |
Why?
|
Periodicals as Topic | 1 | 2003 | 1462 | 0.010 |
Why?
|
Thrombolytic Therapy | 1 | 2000 | 2059 | 0.010 |
Why?
|
Heparin | 1 | 1999 | 1630 | 0.010 |
Why?
|
Blood Platelets | 1 | 2002 | 2464 | 0.010 |
Why?
|
Cross Infection | 1 | 2000 | 1427 | 0.010 |
Why?
|
Pyridines | 1 | 2002 | 2888 | 0.010 |
Why?
|
Bacteremia | 1 | 1997 | 989 | 0.010 |
Why?
|
Pilot Projects | 1 | 2003 | 8733 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 1999 | 6493 | 0.000 |
Why?
|
Obesity | 1 | 1991 | 13075 | 0.000 |
Why?
|
Neoplasms | 1 | 1997 | 22340 | 0.000 |
Why?
|
Hypoglycemic Agents | 1 | 2001 | 3110 | 0.000 |
Why?
|
RNA, Messenger | 1 | 2002 | 12769 | 0.000 |
Why?
|
Cytokines | 1 | 2002 | 7421 | 0.000 |
Why?
|
Cells, Cultured | 1 | 2002 | 18973 | 0.000 |
Why?
|
Stress, Psychological | 1 | 2002 | 4533 | 0.000 |
Why?
|
Peptide Fragments | 1 | 1999 | 5125 | 0.000 |
Why?
|
Central Nervous System Diseases | 1 | 1984 | 518 | 0.000 |
Why?
|
T-Lymphocytes | 1 | 1997 | 10261 | 0.000 |
Why?
|
Developmental Disabilities | 1 | 1984 | 1519 | 0.000 |
Why?
|
Mice | 1 | 2002 | 81818 | 0.000 |
Why?
|
Antineoplastic Agents | 1 | 1997 | 13648 | 0.000 |
Why?
|
Health Status | 1 | 1984 | 4080 | 0.000 |
Why?
|
Socioeconomic Factors | 1 | 1984 | 7836 | 0.000 |
Why?
|
Patient Readmission | 1 | 1984 | 3286 | 0.000 |
Why?
|
Infant, Newborn | 1 | 1984 | 26349 | 0.000 |
Why?
|